FDA approves Xarelto to prevent stroke in people with common type of abnormal heart rhythm

[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

 



Title: FDA approves Xarelto to prevent stroke in people with common type of abnormal heart rhythm

You are subscribed to FDA Press Releases for U.S. Food & Drug Administration (FDA).

This information has recently been updated and is now available.

 

11/04/2011 01:20 PM EDT

The U.S. Food and Drug Administration today approved the anti-clotting drug Xarelto (rivaroxaban) to reduce the risk of stroke in people who have abnormal heart rhythm (non-valvular atrial fibrillation).

.


This email was sent to list-fda@xxxxxxxxxxx using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420 Powered by GovDelivery

[Index of Archives]     [CDC News]     [NIH News]     [USDA News]     [Steve's Art]     [Camping in Yosemite]     [PhotoForum]     [SB Lupus]     [STB]

  Powered by Linux